

medicare



Cystic fibrosis – lumacaftor+ivacaftor or tezacaftor+ivacaftor – initial authority application

Online PBS Authorities

You do not need to complete this form if you use the **Online PBS Authorities** system.

For more information and how to access the **Online PBS Authorities** system, go to **servicesaustralia.gov.au/hppbsauthorities**

When to use this form

Use this form to apply for **initial** PBS-subsidised lumacaftor+ivacaftor or tezacaftor+ivacaftor for patients with cystic fibrosis.

Important information

Initial applications to start PBS-subsidised treatment can be made using the **Online PBS Authorities** system or in writing and must include sufficient information to determine the patient's eligibility according to the PBS criteria.

Under no circumstances will phone approvals be granted for cystic fibrosis **initial** authority applications.

The information in this form is correct at the time of publishing and may be subject to change.

Continuing treatment

This form is ONLY for initial treatment.

Applications for **continuing** treatment can be made using the **Online PBS Authorities** system or in writing and must include sufficient information to determine the patient's eligibility according to the PBS criteria.

Section 100 arrangements for lumacaftor+ivacaftor and tezacaftor+ivacaftor

These items are available to a patient who is attending:

- an approved private hospital, or
- a public hospital

and is a:

- day admitted patient
- non-admitted patient, or
- patient on discharge.

These items are not available as a PBS benefit for in-patients of a public hospital.

The hospital name and provider number must be included in this authority form.

For more information

Go to servicesaustralia.gov.au/healthprofessionals

PB243.2410 **1 of 3**





Cystic fibrosis – lumacaftor+ivacaftor or tezacaftor+ivacaftor – initial authority application



Online PBS Authorities You do not need to complete this form if you use the Online PBS Authorities system. Go to servicesaustralia.gov.au/hppbsauthorities **Patient's details** Medicare card number Department of Veterans' Affairs card number Mrs | Miss | Ms Family name First given name 3 Date of birth (DD MM YYYY) Prescriber's details Prescriber number Family name First given name Business phone number (including area code) Alternative phone number (including area code)

Hospital details			
7	7 Hospital name		
	This hospital is a:		
	public hospital		
	private hospital		
8	Hospital provider number		
Conditions and criteria			
	qualify for PBS authority approval, the following conditions ust be met.		
9	The patient is:		
	1 year or over, applying for lumacaftor+ivacaftor granules Go to 11		
	6 to 11 years, applying for lumacaftor+ivacaftor only		
	12 years or over.		
10	The patient has:		
	chronic sinopulmonary disease		
	or		
	gastrointestinal and nutritional abnormalities.		
11			
	by a specialist respiratory physician with expertise in cystic fibrosis		
or			
	in consultation with a specialist respiratory physician with expertise in cystic fibrosis (if attendance is not possible due to geographic isolation).		
12	The patient is being treated:		
in a centre with expertise in cystic fibrosis			
or			
	in consultation with a centre with expertise in cystic fibrosis (if attendance is not possible due to geographic isolation).		



MCA0PB243 2410

13	The patient:	Privacy notice
	is homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene	20 Personal information is protected by law (including the Privacy Act 1988) and is collected by Services Australia for the
	or (tezacaftor+ivacaftor only)	purposes of assessing and processing this authority application
	has at least one residual function (RF) mutation in the CFTR gene that is responsive to tezacaftor with ivacaftor.	Personal information may be used by Services Australia, or given to other parties where the individual has agreed to this, or
14	Provide details of the pathology report substantiating the patient has the relevant CFTR gene mutation:	where it is required or authorised by law (including for the purpose of research or conducting investigations).
	Name of the pathology report provider	More information about the way in which Services Australia manages personal information, including our privacy policy, can be found at servicesaustralia.gov.au/privacypolicy
	Date of the pathology report (DD MM YYYY)	Prescriber's declaration
	Unique identifying number/code	You do not need to sign the declaration if you complete this form
		using Adobe Acrobat Reader and return this form through Health
15	Is this treatment the sole PBS-subsidised CFTR modulator	Professional Online Services (HPOS) at servicesaustralia.gov.au/hpos
	therapy for this condition?	21 I declare that:
	Yes	I am aware that this patient must meet the criteria listed in
16	No \\ Will the treatment be given concomitantly with standard therapy	the current Schedule of Pharmaceutical Benefits to be eligible for this medicine.
	for this condition? Yes	I have informed the patient that their personal information
	No	(including health information) will be disclosed to Services Australia for the purposes of assessing and processing this
17	The patient, applying for:	authority application.
	lumacaftor+ivacaftor, is not currently receiving one of the strong CYP3A4 inducers outlined in the Product Information	 I have provided details of the proposed prescription(s) and the relevant attachments as specified in the Pharmaceutical Benefits Scheme restriction.
	tezacaftor+ivacaftor, is not currently receiving one of the CYP3A4 inducers listed in the restrictions.	 the information I have provided in this form is complete and correct.
12	Provide current CYP3A4 inhibitors, CYP3A4 inducers and	I understand that:
10	IV antibiotics, if applicable	• giving false or misleading information is a serious offence.
		I have read, understood and agree to the above.
		Date (DD MM YYYY) (you must date this declaration)
		Prescriber's signature (only required if returning by post)
Cho	ecklist	
19	The relevant attachments need to be provided with	Debender Wie fann
	this form.	Returning this form
	Details of the proposed prescription(s).	Return this form, details of the proposed prescription(s) and any relevant attachments:
		online (no signature required), upload through HPOS at servicesaustralia.gov.au/hpos
		or
		by post (signature required) to
		Services Australia Complex Drugs Programs
		Reply Paid 9826 HOBART TAS 7001